PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways

Mol Cell Neurosci. 2000 Mar;15(3):314-29. doi: 10.1006/mcne.1999.0827.

Abstract

In this paper we address the linking of platelet-derived growth factor (PDGF) and basic fibroblast growth factor (FGF-2) to intracellular signaling molecules in oligodendrocyte progenitors. It is demonstrated that both growth factors activate downstream targets similar to those shown for protein kinase C (PKC) activation. Yet, neither the arrest of terminal oligodendrocyte differentiation nor the proliferation induced by PDGF or FGF-2 can be antagonized by inhibition of PKC. Rather, p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, and pp70 S6 kinase were found to be necessary for the mitogenic activity of PDGF and FGF-2. Paradoxically, these kinases were also necessary for the onset of oligodendrocyte differentiation in control cells. In addition, cAMP-dependent kinase A (PKA) activation inhibited the mitogenic response of oligodendrocyte progenitors to FGF-2. Taken together, the molecular mechanism that controls oligodendrocyte lineage progression is operated by at least two signal pathways, which interfere either with proliferation and/or differentiation of oligodendrocyte progenitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Differentiation / drug effects
  • Cell Division / drug effects
  • Cyclic AMP / physiology
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / physiology
  • Enzyme Inhibitors / pharmacology
  • Estrenes / pharmacology
  • Fibroblast Growth Factor 2 / pharmacology*
  • Flavonoids / pharmacology
  • Genistein / pharmacology
  • Imidazoles / pharmacology
  • Intracellular Signaling Peptides and Proteins*
  • MAP Kinase Signaling System / drug effects
  • Membrane Proteins*
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / physiology
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / physiology
  • Myristoylated Alanine-Rich C Kinase Substrate
  • Nerve Tissue Proteins / physiology
  • Oligodendroglia / drug effects*
  • Oligodendroglia / physiology
  • Phosphorylation
  • Platelet-Derived Growth Factor / pharmacology*
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / physiology
  • Protein Processing, Post-Translational
  • Proteins / metabolism
  • Pyridines / pharmacology
  • Pyrrolidinones / pharmacology
  • Rats
  • Ribosomal Protein S6 Kinases / antagonists & inhibitors
  • Ribosomal Protein S6 Kinases / physiology
  • Signal Transduction / drug effects*
  • Sirolimus / pharmacology
  • Stem Cells / drug effects*
  • Stem Cells / physiology
  • p38 Mitogen-Activated Protein Kinases

Substances

  • Enzyme Inhibitors
  • Estrenes
  • Flavonoids
  • Imidazoles
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Nerve Tissue Proteins
  • Platelet-Derived Growth Factor
  • Proteins
  • Pyridines
  • Pyrrolidinones
  • Fibroblast Growth Factor 2
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • Myristoylated Alanine-Rich C Kinase Substrate
  • Genistein
  • Cyclic AMP
  • Ribosomal Protein S6 Kinases
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinases
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Sirolimus